查看購物車
  • English
  • Japanese
  • Korean
轉移性去勢敏感性前列腺癌 (mCSPC) 市場 - 全球和區域分析：按治療方法類型、按地區分類 - 分析和預測 (2025-2035)
市場調查報告書
商品編碼
1906307

轉移性去勢敏感性前列腺癌 (mCSPC) 市場 - 全球和區域分析：按治療方法類型、按地區分類 - 分析和預測 (2025-2035)

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 90 Pages | 商品交期: 1-5個工作天內

價格

轉移性去勢敏感性前列腺癌（mCSPC）市場－分析與預測（2025-2035）

轉移性去勢敏感性前列腺癌 (mCSPC) 是前列腺癌的一個亞型，其特徵是癌細胞擴散到遠端部位，即使患者仍能對荷爾蒙療法反應。

前列腺癌的這一階段對雄性激素剝奪療法（ADT）敏感，但隨著時間的推移，可能會進展為去勢抗性前列腺癌（CRPC）。轉移性去勢抵抗性攝護腺癌（mCSPC）的主要治療目標是延緩疾病進展、緩解症狀並提高患者的生活品質。

前列腺癌發生率的不斷上升，以及人們對前列腺癌的意識提升和早期診斷技術的進步，是mCSPC市場的主要促進因素。隨著全球人口老化，mCSPC病例數預計將會增加，從而促進市場擴張。此外，個人化醫療的興起，以及Abiraterone、Enzalutamide和多西他賽等標靶治療方法和生物製藥的應用，預計也將推動mCSPC市場的成長。

除了雄性激素剝奪療法外，包括免疫療法和標靶治療（例如PARP抑制劑和查核點抑制劑）在內的新一代療法的日益普及，正在徹底改變轉移性去勢抵抗性前列腺癌（mCSPC）的治療方法。這些先進治療方法針對驅動癌症進展的分子機制，為具有高風險疾病特徵的患者帶來了新的希望。此外，生物標記、液態生物檢體和基因組分析等診斷工具的進步，提高了早期檢測率，並實現了更準確的風險分層。如今，透過識別mCSPC患者體內特定的基因改變（例如BRCA1/BRCA2和PTEN缺陷），臨床醫生可以根據每位患者的個別需求制定治療方案，從而顯著改善臨床療效並延緩疾病進展。

此外，精準醫療的興起和以個人化治療為重點的臨床試驗的擴展，帶來了巨大的成長機會。製藥和生技公司正在加大研發投入，以期找到更有效的治療方法，並利用遺傳學知識和腫瘤特徵開發新的標靶治療。

儘管前景樂觀，但轉移性去勢抵抗性前列腺癌（mCSPC）市場仍面臨挑戰。其中一個主要障礙是治療研發高成本，尤其是新型治療方法，這可能會限制部分患者（特別是中低收入地區的患者）獲得治療的機會。此外，雖然mCSPC的治療已取得顯著進展，但長期存活率仍然是一個重要問題，因為大多數患者最終會發展為去勢抗性前列腺癌（CRPC）。

轉移性去勢敏感性前列腺癌 (mCSPC) 市場的主要企業，包括強生公司、安斯泰來製藥公司和輝瑞公司，正處於 mCSPC 治療研發的前沿。這些公司正投入大量資金拓展其癌症治療產品線，專注於研發新一代荷爾蒙療法和新型免疫療法，旨在為 mCSPC 患者提供更有效、更持久的治療方案。預計這些努力將繼續推動 mCSPC 治療的進步，並改善全球患者的治療效果。

全球轉移性去勢敏感性前列腺癌 (mCSPC) 市場競爭格局複雜多樣，眾多公司遍佈各個地區，提供種類繁多的產品。隨著需求不斷成長，尤其是在亞太和拉丁美洲等新興市場，區域性和本地公司預計將在市場成長中發揮關鍵作用。隨著消費者偏好轉向更隱密、舒適和經濟的解決方案，轉移性去勢敏感性前列腺癌 (mCSPC) 市場將持續發展，為現有企業和新興企業創造新的機會。

市場區隔:

細分 1：按治療方法

  • 化療
  • 荷爾蒙療法
  • 免疫療法
  • 其他治療方法

細分2：按區域

  • 北美洲
  • 歐洲
  • 亞太地區

隨著轉移性去勢敏感性前列腺癌（mCSPC）市場的不斷發展，個人化癌症治療的開發、人工智慧在提高診斷準確性方面的應用日益廣泛以及再生醫學的整合等新興趨勢，有​​望重塑mCSPC的治療格局。細胞和基因療法的進步，以及骨標靶治療的突破，將在改變mCSPC的治療管理方面發揮關鍵作用。此外，對罕見癌症的投入增加以及病患權益計劃工作的拓展，預計也將持續加速治療創新。

全球轉移性去勢敏感性前列腺癌 (mCSPC) 市場預計將長期成長。公眾意識的提高、診斷技術的進步以及治療方案的不斷豐富預計將推動市場發展。儘管高昂的治療費用和市場進入等挑戰依然存在，但精準醫療的進步和新型治療方法的持續研發正為市場相關人員創造巨大的機會。成熟的製藥公司和新興的生物技術公司都將在拓展治療選擇、提高轉移性去勢敏感性前列腺癌 (mCSPC) 患者的生存率和生活品質方面發揮關鍵作用。

目錄

執行摘要

第1章 市場：產業展望

  • 介紹
  • 市場趨勢
  • 法律規範
  • 轉移性去勢敏感性前列腺癌（mCSPC）的流行病學分析
  • 在研藥物分析
  • 市場動態
    • 影響分析
    • 市場促進因素
    • 市場挑戰
    • 市場機遇

2. 2024-2035年全球轉移性去勢敏感性前列腺癌（mCSPC）市場依治療類型分類

  • 概述
  • 化療
  • 荷爾蒙療法
  • 免疫療法
  • 其他

3. 2024-2035年全球轉移性去勢敏感性前列腺癌（mCSPC）市場（按地區分類）

  • 北美洲
    • 主要發現
    • 市場動態
    • 市場規模及預測
  • 歐洲
    • 主要發現
    • 市場動態
    • 市場規模及預測
  • 亞太地區
    • 主要發現
    • 市場動態
    • 市場規模及預測

4. 全球轉移性去勢敏感性前列腺癌（mCSPC）市場：競爭格局與公司概況

  • 關鍵發展和策略
    • 併購
    • 協同活動
    • 業務拓展及資金籌措
    • 產品上市及核准
    • 其他活動
  • 公司簡介
    • Pfizer Inc.
    • Johnson & Johnson
    • Astellas Pharma Inc.
    • AstraZeneca
    • Bayer
    • 其他

第5章調查方法

Product Code: BHL3536SA

Global Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market, Analysis and Forecast: 2025-2035

Metastatic castration-sensitive prostate cancer (mCSPC) is a subtype of prostate cancer that is characterized by the spread of cancer cells to distant sites, despite the patient still having the ability to respond to hormonal therapy. This stage of prostate cancer is sensitive to androgen deprivation therapy (ADT), but over time, it can progress into castration-resistant prostate cancer (CRPC). The primary treatment goal in mCSPC is to delay disease progression, reduce symptoms, and improve the quality of life for patients.

The increasing prevalence of prostate cancer, coupled with the rising awareness and improved diagnostic techniques for early detection, is are significant driver for the mCSPC market. As the global population ages, the number of mCSPC cases is expected to rise, contributing to market expansion. Furthermore, the shift toward personalized medicine, with more targeted treatments and biologics such as abiraterone, enzalutamide, and docetaxel, is expected to fuel growth in the mCSPC market.

In addition to androgen deprivation therapy, the growing adoption of next-generation therapies, including immunotherapy and targeted treatments such as PARP inhibitors and checkpoint inhibitors, is revolutionizing the way mCSPC is treated. These advanced therapies offer new hope for patients with high-risk disease profiles, as they aim to target the molecular mechanisms driving cancer progression. Further, advancements in diagnostic tools like biomarkers, liquid biopsy, and genomic profiling are improving early detection and allowing for more accurate risk stratification. The ability to identify specific genetic mutations, such as BRCA1/BRCA2 and PTEN loss, in mCSPC patients is enabling clinicians to tailor treatments to the individual needs of patients, which significantly improves clinical outcomes and may slow disease progression.

Additionally, the rise of precision medicine and the expansion of clinical trials focusing on personalized therapies present substantial growth opportunities. Pharmaceutical companies and biotech firms are increasingly investing in research to identify more effective treatment regimens, leveraging genetic insights and tumor characteristics to develop new targeted therapies.

Despite the positive outlook, challenges remain for the mCSPC market. One of the major obstacles is the high cost of treatment development, particularly for novel therapies, which may limit access for some patients, especially in low and middle-income regions. Additionally, while mCSPC treatments have made significant strides, long-term survival rates remain a key concern, as most patients eventually progress to castration-resistant prostate cancer (CRPC).

Leading companies in the metastatic castration-sensitive prostate cancer (mCSPC) market, such as Johnson & Johnson, Astellas Pharma Inc., and Pfizer Inc., are at the forefront of metastatic castration-sensitive prostate cancer (mCSPC) treatment development. These players are investing heavily in the expansion of their oncology pipelines, focusing on both next-generation hormonal therapies and novel immunotherapies to provide more effective and longer-lasting solutions for mCSPC patients. These efforts are expected to drive the continued evolution of the metastatic castration-sensitive prostate cancer (mCSPC) treatment landscape while improving patient outcomes globally.

The competitive landscape of the global metastatic castration-sensitive prostate cancer (mCSPC) market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market's growth, especially as demand increases in emerging markets such as the Asia-Pacific and Latin America. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the metastatic castration-sensitive prostate cancer (mCSPC) market will continue to evolve, fostering new opportunities for both established and emerging companies.

Market Segmentation:

Segmentation 1: by Therapy Type

  • Chemotherapy
  • Hormonal Therapies
  • Immunotherapy
  • Other Therapy Types

Segmentation 2: by Region

  • North America
  • Europe
  • Asia-Pacific

As the metastatic castration-sensitive prostate cancer (mCSPC) market evolves, emerging trends such as the development of personalized cancer therapies, the increasing use of AI for diagnostic precision, and the integration of regenerative medicine are poised to redefine the treatment landscape. Advances in cell and gene therapy, coupled with breakthroughs in bone-targeted therapies, will play an instrumental role in transforming the management of metastatic castration-sensitive prostate cancer (mCSPC). Increased funding for rare cancers and growing patient advocacy efforts will also continue to accelerate progress in treatment innovation.

The global metastatic castration-sensitive prostate cancer (mCSPC) market is positioned for long-term growth. Rising awareness, improved diagnostic techniques, and the expansion of therapeutic pipelines are expected to drive market development. While challenges such as high treatment costs and market access remain, the progress in precision medicine and the continuous development of novel therapies create substantial opportunities for market players. Both established pharmaceutical companies and emerging biotech innovators will play critical roles in advancing treatment options and improving the survival and quality of life for patients with metastatic castration-sensitive prostate cancer (mCSPC).

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Market: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Epidemiological Analysis of Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
  • 1.5 Pipeline Drugs Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Challenges
    • 1.6.4 Market Opportunities

2. Global Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market (by Therapy Type), ($Million), 2024-2035

  • 2.1 Overview
  • 2.2 Chemotherapy
  • 2.3 Hormonal Therapies
  • 2.4 Immunotherapy
  • 2.5 Other Therapy Types

3. Global Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market (Region), ($Million), 2024-2035

  • 3.1 North America
    • 3.1.1 Key Findings
    • 3.1.2 Market Dynamics
    • 3.1.3 Market Sizing and Forecast
      • 3.1.3.1 North America Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market, by Country
        • 3.1.3.1.1 U.S.
  • 3.2 Europe
    • 3.2.1 Key Findings
    • 3.2.2 Market Dynamics
    • 3.2.3 Market Sizing and Forecast
      • 3.2.3.1 Europe Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market, by Country
        • 3.2.3.1.1 Germany
        • 3.2.3.1.2 U.K.
        • 3.2.3.1.3 France
        • 3.2.3.1.4 Italy
        • 3.2.3.1.5 Spain
        • 3.2.3.1.6 Rest-of-Europe
  • 3.3 Asia Pacific
    • 3.3.1 Key Findings
    • 3.3.2 Market Dynamics
    • 3.3.3 Market Sizing and Forecast
      • 3.3.3.1 Asia Pacific Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market, by Country
        • 3.3.3.1.1 Japan

4. Global Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market: Competitive Landscape and Company Profiles

  • 4.1 Key Developments and Strategies
    • 4.1.1 Mergers and Acquisitions
    • 4.1.2 Synergistic Activities
    • 4.1.3 Business Expansions and Funding
    • 4.1.4 Product Launches and Approvals
    • 4.1.5 Other Activities
  • 4.2 Company Profiles
    • 4.2.1 Pfizer Inc.
      • 4.2.1.1 Overview
      • 4.2.1.2 Top Products / Product Portfolio
      • 4.2.1.3 Top Competitors
      • 4.2.1.4 Target Customers/End-Users
      • 4.2.1.5 Key Personnel
      • 4.2.1.6 Analyst View
    • 4.2.2 Johnson & Johnson
      • 4.2.2.1 Overview
      • 4.2.2.2 Top Products / Product Portfolio
      • 4.2.2.3 Top Competitors
      • 4.2.2.4 Target Customers/End-Users
      • 4.2.2.5 Key Personnel
      • 4.2.2.6 Analyst View
    • 4.2.3 Astellas Pharma Inc.
      • 4.2.3.1 Overview
      • 4.2.3.2 Top Products / Product Portfolio
      • 4.2.3.3 Top Competitors
      • 4.2.3.4 Target Customers/End-Users
      • 4.2.3.5 Key Personnel
      • 4.2.3.6 Analyst View
    • 4.2.4 AstraZeneca
      • 4.2.4.1 Overview
      • 4.2.4.2 Top Products / Product Portfolio
      • 4.2.4.3 Top Competitors
      • 4.2.4.4 Target Customers/End-Users
      • 4.2.4.5 Key Personnel
      • 4.2.4.6 Analyst View
    • 4.2.5 Bayer
      • 4.2.5.1 Overview
      • 4.2.5.2 Top Products / Product Portfolio
      • 4.2.5.3 Top Competitors
      • 4.2.5.4 Target Customers/End-Users
      • 4.2.5.5 Key Personnel
      • 4.2.5.6 Analyst View
    • 4.2.6 Others

5. Research Methodology

List of Figures

  • Figure: Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market (by Scenario), $Million, 2024, 2030, and 2035
  • Figure: Global Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market, 2024 and 2035
  • Figure: Global Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market Key Trends, Impact Analysis
  • Figure: North America Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market, $Million, 2024-2035
  • Figure: Europe Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market, $Million, 2024-2035
  • Figure: Asia-Pacific Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market, $Million, 2024-2035

List of Tables

  • Table: Market Snapshot
  • Table: Market Dynamics
  • Table: Global Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market (by Therapy Type), $Million, 2024-2035
  • Table: Global Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market (by Region), $Million, 2024-2035